Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Indiana's workforce is feeling pressure to return to the office, but a good portion of employees still like hybrid work. Is ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Eli Lilly And Co (LLY) stock saw a decline, ending the day at $810.43 which represents a decrease of $-0.65 or -0.08% from the prior close of $811.08. The stock opened at $804.27 and touched a low of ...

He also sardonically targeted co-host David Faber and said “Look I’m sure that when they discovered the cotton gin, and ...

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...